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Abstract
Background: Protein-energy malnutrition is common in patients with end-stage liver disease undergoing liver 
transplantation. We examined the characteristics of nutritional status and impact of pre-admission branched-chain-
amino-acids treatment on skeletal muscle mass, nutritional/metabolic parameters and on post-transplant outcomes.
Methodology: Preoperative skeletal muscle mass and nutritional/metabolic parameter levels were compared 
in 129 patients undergoing adult-to-adult living donor liver transplantation whether received branched-chain-amino-
acids treatment before admission or not. We examined relationships among these parameters, and risk factors for 
post-transplant bacteremia and early mortality after LT focusing on nutritional parameters.
Results: Pre-albumin and branched-chain-amino-acids-to-tyrosine ratio were significantly higher while tyrosine 
was lower in branched-chain-amino-acids-pre-supplemented than non-pre-supplemented group, while skeletal 
muscle mass, total lymphocyte count, zinc, branched-chain-amino-acids and ammonia levels were not significantly 
different. Skeletal muscle mass positively correlated with tyrosine (r=0.437, P<0.001) and branched-chain-amino-
acids (r=0.282, P=0.001) and negatively with branched-chain-amino-acids-to-tyrosine-ratio (r=-0.259, P=0.003). 
Multivariate predictors of post-transplant bacteremia were: Child-Pugh class C (P=0.012), low preoperative total 
lymphocyte count (P=0.027), operative blood loss ≥ 10 L (P=0.039) and absence of pre-admission branched-chain-
amino-acids treatment (P=0.040). Nutritional/metabolic parameters and pre-admission branched-chain-amino-acids 
treatment were not crucial for post-transplant early mortality.
Conclusion: Pre-admission branched-chain-amino-acid therapy could ameliorate preoperative amino acid 
imbalance and the incidence of post-transplant bacteremia.
Keywords: Branched-chain amino acids; Bioelectrical impedance 
analysis; Skeletal muscle mass; Sarcopenia; Zinc
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AAAs: Aromatic Amino Acids; BCAAs: Branched-Chain Amino 
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Ratio; CP: Child-Pugh; DDLT: Deceased Donor Liver Transplantation; 
DSM-BIA: Direct Segmental BIA; HE: Hepatic Encephalopathy; LC: 
Liver Cirrhosis; LDLT: Living Donor Liver Transplantation; LT: Liver 
Transplantation; MELD: Model For End-Stage Liver Diseases; NH3: 
Ammonia; PA: Pre-Albumin; SMM: Skeletal Muscle Mass; TLC: Total 
Lymphocyte Count; TYR: Tyrosine; Zn: Zinc
Introduction 
Derangements of various serum biochemical nutritional parameters 
including zinc, pre-albumin, branched-chain amino acids (BCAA), 
tyrosine, total lymphocyte count and the related metabolic parameters 
as the molar ratio of BCAA-to-tyrosine (BTR) and ammonia, are not 
uncommon in patients with end-stage liver disease undergoing liver 
transplantation (LT) due to hepatic debilitating pathology and its 
medical management [1-5].
Patients with decompensated liver cirrhosis frequently receive 
nutritional therapy with a nutrient mixture enriched with BCAA 
or BCAA nutrients. BCAA supplementation was reported to delay 
reduction of hepatic reserve in patients with end-stage liver disease [6]. 
However, the effect on patients undergoing living donor LT (LDLT) 
is unclear. Moreover, the nutritional status and relationships between 
nutritional parameters including skeletal muscle mass and zinc in such 
patients are not well understood. 
We recently reported that skeletal muscle mass had a significant 
negative correlation with BTR and low preoperative skeletal muscle 
mass to be closely involved with post-transplant mortality [7]. 
However, neither the impact of both pre-admission BCAA treatment 
and preoperative levels of nutritional/metabolic parameters on post-
transplant outcomes nor the reason of the negative relationship is clear.
The aim of the present study was therefore to examine the 
characteristics of nutritional status and the impact of pre-admission 
BCAA treatment on both skeletal muscle mass and nutritional/
metabolic parameter levels in LDLT candidates. Additionally, we 
assessed relationships among these parameters, especially with skeletal 
muscle mass and zinc levels, and examined risk factor for bacteremia 
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by common skin contaminants, bacteremia was considered significant 
only if an organism was isolated from two blood cultures and clinical 
signs of infection were evident.
Subgroups assignment
Sixty-six patients out of 129 received BCAA treatment before 
admission to LDLT for a duration of at least a few months, either in the 
form of 1 to 3 packets of BCAA-enriched nutrient mixture (Aminoleban 
EN®; Otsuka Pharmaceutical Co., Tokyo, Japan) per day (50-150 g/day), 
(n=32) or 3 packets of BCAA granules (Livact®; Ajinomoto Pharma Co., 
Tokyo, Japan) per day (12.45 g/day), (n=34). The other 63 patients did 
not receive any BCAA supplements before admission. BCAA were 
introduced at the discretion of the attending physician before referral 
of a potential recipient for LDLT. After admission to LDLT, all patients 
received the same perioperative nutritional therapy as described before 
[7].
Analyzed parameters
Preoperative laboratory data of nutritional/metabolic parameters 
on admission were retrospectively reviewed from the clinical charts 
of the recipients. The standard reference intervals of these parameters 
at our institute were: zinc (65-110 µg/dL), prealbumin (20-40 mg/
dL), total lymphocyte count (1200-3200/µL), ammonia (20-60 µg/dL), 
BCAA (344-713 µmol/L), tyrosine (53-98 µmol/L) and the BTR (4.4-
9.3). 
Skeletal muscle mass and parameter levels on admission were 
examined. Correlations of skeletal muscle mass and all parameters and 
those of zinc with other parameters were examined. Because BCAA 
treatment before admission may affect BCAA blood level, we separately 
analyzed relationship between skeletal muscle mass and BCAA in 
groups with or without BCAA pretreatment. A transversal study was 
performed where preoperative nutritional/metabolic parameters and 
skeletal muscle mass, length of postoperative hospital stay, incidence of 
postoperative bacteremia, and biopsy-proven acute cellular rejection 
were examined in patients admitted to LDLT according to whether 
they received BCAA treatment before admission to LDLT (BCAA+, 
n=66) or not (BCAA-, n=63). 
Moreover, we examined risk factors for post-transplant death 
within 90 days after LT and post-transplant bacteremia focusing on 
preoperative nutritional/metabolic parameter levels and pre-admission 
BCAA treatment [18].
Statistical analysis
Data was summarized as mean ± standard deviation (SD) for 
continuous variables. Categorical variables were compared using the χ2 
test or Fisher’s exact test where appropriate. Continuous variables were 
non-parametrically analyzed using the Mann-Whitney U test with the 
sequential step-down Holm-Bonferroni method applied to adjust for 
multiple testing [17]. Correlation between two variables was analyzed 
using Spearman’s rank correlation coefficient. Any variable identified 
as significant (P<0.05) in univariate analysis using the above tests was 
considered a candidate for multivariate analysis using multiple logistic 
regression models. Survival rate was calculated using Kaplan-Meier 
methods with differences evaluated using log-rank testing. Two tailed 
P<0.05 was considered significant. All statistical data were generated 
using JMP 5.0.1 (SAS Institute, Cary, NC) and Prism 6.02 (GraphPad 
Software, Inc., La Jolla, CA, USA).
and early mortality after LT focusing on nutritional factors.
Methodology
Patients
Two hundred and eight adult (age ≥ 18 years) patients underwent 
primary LDLT at Kyoto University Hospital between February 2008 
and August 2012. Excluded from the study were 15 patients with acute 
liver failure as an indication for LT for the following reasons: First, the 
pathophysiology and nutritional status is different from patients with 
other end-stage liver diseases. Second, BCAA supplementation was not 
suitable for those patients and even regarded as a contraindication [8]. 
Third, they could not undergo preoperative bioelectrical impedance 
body composition analysis (BIA) examination due to emergent LT. 
Next, 64 patients who could not undergo BIA per the dietitians, 
limitations of dietitians’ manpower or the hospital’s circumstances 
were further excluded. The study thus comprised 129 patients. There 
were 63 males and 66 females. The median patient age was 53 years 
(range, 19-65 years). The study was approved by the Ethics Committee 
of Kyoto University and conducted in accordance with the Declaration 
of Helsinki of 1996.
The median Model for End-stage Liver Disease (MELD) score was 
19 (range, 4-47). Thirty-seven patients were ABO incompatible, and 
92 were identical or compatible. The Child-Pugh classifications were 
C, B, and A for 78, 42, and 9 patients, respectively. The indications for 
LT were hepatocellular carcinoma (n=36), followed by hepatocellular 
diseases such as hepatitis B or C virus-associated liver cirrhosis (n=32), 
progressive intrahepatic cholestatic diseases including primary biliary 
cirrhosis and primary sclerosing cholangitis (n=24), biliary atresia after 
the Kasai procedure (n=8), alcoholic liver cirrhosis (n=7), metabolic 
liver diseases (n=5), nonalcoholic steatohepatitis (n=4), autoimmune 
hepatitis (n=3) and other causes (n=10). 
In February 2008, we introduced body composition measurements 
on admission for patients undergoing LDLT, using direct segmental 
multi-frequency BIA with eight tactile electrodes (InBody 720; 
Biospace, Tokyo, Japan). The BIA device used 6 frequencies and 
produced 30 impedance values for 5 body segments and takes direct 
impedance measurements from each, unlike conventional BIA 
used before [9,10] which takes only partial measurements and relies 
on formulas to estimate whole body composition. The BIA device 
was reported as an accurate substitute for the dual-energy X-ray 
absorptiometry in measurement of total and appendicular body 
composition [11]. Skeletal muscle mass was measured automatically 
by the InBody 720 and shown as a percent against standard skeletal 
muscle mass calculated by sex and height of each patient. The normal 
skeletal muscle mass ratio obtained by the InBody 720 ranges from 90% 
to 110% of the standard skeletal muscle mass. 
Selection criteria for the recipients as well as surgical techniques for 
recipient operations have been described in detail elsewhere [12,13]. 
Immunosuppressive treatment usually consisted of tacrolimus or 
cyclosporine and low-dose steroids as described elsewhere [14,15]. 
All patients received intravenous antimicrobial prophylaxis with 
ampicillin (0.5 g) and cefotaxime (0.5 g) twice daily for 3 days starting 
30 min before surgery.
Infections were defined using the criteria proposed by the Centers 
for Disease Control and Prevention and based on reports of liver 
transplant patients [16]. The isolation of bacteria other than common 
skin contaminants from a single blood culture in the presence of clinical 
symptoms or of an infection was considered bacteremia. When caused 
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Results
Pretransplant nutritional status
Marked hyperammonemia (94.1 ± 16.8 µg/dL), hypertyrosinemia 
(138.6 ± 12.1 µmol/L), hypozincemia (44.4 ± 12.6 µg/dL), 
hypoprealbuminemia (6.8 ± 2.5 mg/dL) and a decreased total 
lymphocyte count (855.3 ± 207.3/µL), were seen on admission before 
LDLT. Preoperative BCAA level (397.2 ± 56 µmol/L) was low, yet 
still within reference range. Consequently, the BTR (3.1 ± 0.5) was 
subnormal. The median ratio of preoperative skeletal muscle mass was 
92% (range 65%-32%) of the standard muscle mass.
Correlations between parameters
Correlations of preoperative skeletal muscle mass with both 
tyrosine (r=0.437, P<0.001; Figure 1A) and BCAA levels (r=0.282, 
P=0.001; Figure 1B) were significantly positive. Correlation of skeletal 
muscle mass with the BTR was significantly negative (r=-0.259, 
P=0.003; Figure 1C). Subgroup analysis showed that skeletal muscle 
mass remained positively correlated with BCAA in both BCAA-pre-
supplemented group (r=0.257, P=0.039; Figure 1D) and non-pre-
supplemented group (r=0.259, P=0.040; Figure 1E), although the 
correlations between these parameters were weak. No significant 
correlations were identified between skeletal muscle mass and zinc 
(P=0.219), pre-albumin (P=0.143), total lymphocyte count (P=0.716) 
or ammonia (P=0.061).
Correlations of preoperative zinc with pre-albumin (r=0.472, 
P<0.001; Figure 2A), BCAA (r=0.189, P=0.011; Figure 2B) and the 
BTR (r=0.343, P<0.001; Figure 2C) were significantly positive. While, 
correlations of zinc with tyrosine (r=-0.224, P=0.002, Figure 2D) and 
ammonia levels (r=-0.178, P=0.016; Figure 2E) were significantly 
negative, although the correlations between these parameters were 
weak. Significant correlations were not identified between zinc and the 
total lymphocyte count (P=0.750).
The effect of BCAA treatment before admission to LDLT
The clinical characteristics and surgical variables of the patients 
in BCAA+ and BCAA- groups on admission were compared in Table 
1. There were no significant differences in age, sex, body mass index, 
Child-Pugh classification, MELD score, etiology of disease, number 
of ABO-incompatible grafts, donor age, operative blood loss and 
transfusion units (erythrocyte concentrates). 
Pre-albumin level on admission was significantly higher, while 
tyrosine level was significantly lower in the BCAA+ than in BCAA- 
group (P=0.023 and P<0.001), respectively (Table 2). Zinc, BCAA, 
total lymphocyte count and ammonia levels did not significantly 
differ between both groups (P=0.834, P=0.421, P=0.781 and P=0.560), 
respectively. Consequently, the BTR was significantly higher in BCAA+ 
than in BCAA- group (P=0.046). Preoperative skeletal muscle mass did 
not significantly differ between both groups (P=0.143). 
As for post-transplant outcomes, incidence of post-transplant 
bacteremia was significantly lower in BCAA+ than BCAA- group (30% 
versus 52%, P=0.011). However, the incidence of acute cellular rejection 
and the mean length of postoperative hospital stay were similar in the 
two groups (P=0.279, P=0.576, respectively).
Risk factor analysis for early posttransplant mortality
Univariate analysis revealed that neither pre-admission BCAA 
supplementation nor preoperative levels of nutritional/metabolic 
 
BCAA: Branched-Chain Amino Acids; BTR: BCAA-To-Tyrosine Ratio
Figure 1: Correlations between values for skeletal muscle mass with tyrosine 
(A), BCAA (B), BTR (C) in all patients, with BCAA in BCAA-presupplemented 
group (D), and with BCAA in BCAA non-pre-supplemented group (E). 
 
BCAA: Branched-Chain Amino Acids; BTR: BCAA-To-Tyrosine Rate
Figure 2: Correlations between values for zinc with pre-albumin (A), BCAA (B), 
BTR (C), tyrosine (D), and ammonia (E). 
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parameters on admission were significant risk factors for early post-
transplant mortality (Table 3). 
Risk factor analysis for post-transplant bacteremia
Fifty-three patients of 129 developed post-transplant bacteremia. 
Univariate analysis showed that incidence of post-transplant bacteremia 
was significantly higher in patients with Child-Pugh classification 
C (P=0.001), operative blood loss ≥ 10 L (P=0.010), preoperative 
total lymphocyte count <700/µL (P=0.004), and absence of pre-
admission BCAA treatment (P=0.011) (Table 4). Multivariate analysis 
demonstrated four independent adverse risk factors for posttransplant 
bacteremia: Child-Pugh classification C (P=0.012), preoperative total 
lymphocyte count <700/µL (P=0.027), operative blood loss of ≥ 10 L 
(P=0.039) and absence of pre-admission BCAA treatment (P=0.040) 
(Table 5).
Discussion
This retrospective study is the first to collectively examine pre-
transplant characteristics of nutritional/metabolic parameters and 
skeletal muscle mass among patients with end-stage liver disease 
undergoing LDLT and investigate the impact of preoperative BCAA 
treatment before admission. Moreover, BCAA treatment before 
admission improved nutritional status in LDLT candidates. BCAA 
treatment before admission and preoperative TLC level has potential 
impacts on the incidence of post-transplant bacteremia. Selberg 
et al. [18] conducted a prospective cohort study of nutritional and 
metabolic parameters in 150 patients with end-stage liver disease 
undergoing LT. They showed that a poor nutritional state as well as 
hypermetabolism was not only an important prognostic factor in the 
evaluation of the risks of patients but also adversely affected survival 
after LT, the concept of which is in line with our recent report showing 
Variable BCAA+ (n=66) BCAA- (n=63) P
Donor age (years) 43.7 ± 10.6 43.7 ± 10.6 0.465
Recipient age at transplantation (years) 52.2 ± 11.1  47.0 ± 14.4 0.148
Gender (male/female) 33/33 30/33 0.861
Body mass index on admission (kg/m2)  23.0 ± 4.3 21.6 ± 4.4 0.153
Underlying disease - - -
HCC with viral hepatitis 22 14 0.168
Viral hepatitis B/C related cirrhosis 15 17 0.684
PBC/PSC 12 12 0.899
Biliary atresis post Kasai 3 5 0.486
Alcoholic cirrhosis 4 3 0.745
Metabolic disease 2 3 0.675
NASH 2 2 0.962
Autoimmune hepatitis 2 1 0.587
Others 4 6 0.534
ABO compatibility - - 0.057
Identical/compatible 42 50 -
incompatible 24 13 -
Child-Pugh classification (A, B/C)  20/46 31/32 0.366
MELD score 18.3 ± 6.9 20.5 ± 8.2 0.754
Graft type - - 0.259
Left lobe 27 32 -
Right lobe 39 31 -
Graft weight (g) 541.1 ± 153.5 493.5 ± 113.2 0.754
Surgical duration (min) 914 ± 127 957 ± 167 0.544
Intra-operative blood loss (ml) 9556 ± 3544 9256 ± 3334 0.964
Intra-operative erythrocyte transfusion (U) 20.9 ± 10.6  21.3 ± 10.5 0.132
*Including one domino graft
†BCAA: Branched-Chain Amino Acids; BCAA+: Received pre-admission BCAA treatment; BCAA-: Did not receive pre-admission BCAA treatment; HCC: Hepatocellular 
Carcinoma; PBC: Primary Biliary Cirrhosis; PSC: Primary Sclerosing Cholangitis; NASH: Non-Alcoholic Steatohepatitis; MELD: Model for End-Stage Liver Disease
Table 1: Patient characteristics according to branched chain amino acids treatment given before admission.
Variable BCAA+ (n=66) BCAA- (n=63) P P*
Zinc (µg/dL) 40.5 ± 10.2 47.2 ± 11.2 0.834 -
Prealbumin (mg/dL) 7.9 ± 2.1 5.2 ± 2.1 0.0038 0.023
BCAA (µmol/L) 401.3 ± 48.2 392.7 ± 49.5 0.421 -
Tyrosine (µmol/L) 124.7 ± 12.4 149.2 ± 13.1 <0.001 <0.001
BTR 3.7 ± 0.3 3.0 ± 0.3 0.0066 0.046
Total lymphocyte count 893.3 ± 213.1 841.9 ± 215.6 0.781 -
Ammonia (µg/dL) 96.1 ± 17.3 93.5 ± 15.3 0.56 -
Skeletal muscle mass (%) 96.8 ± 13.4 92.7 ± 12.5 0.143 -
†BCAA: Branched-Chain Amino Acids; BCAA+: Patients who received pre-admission BCAA treatment; BCAA-: Patients who did not receive pre-admission BCAA 
treatment; BTR: BCAA-To-Tyrosine Ratio
Table 2: Levels of nutritional/metabolic parameters and skeletal muscle mass on admission according to pre-admission BCAA supplementation.
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Variable 90-days OS P
Recipient Age (y)
<60 (n=88) 86% 0.283
≥ 60 (n=41) 91%
Donor Age (y)
<50 (n=93) 91% 0.335
≥ 50 (n=36) 85%
Sex
Male (n=63) 91% 0.143
Female (n=66) 83%
Original disease
HCC (n=36) 81% 0.144
Non-HCC (n=93) 90%
ABO blood type
Compatible (n=92) 90% 0.087
Incompatible (n=37) 81%
Child-Pugh classification
A, B (n=51) 91% 0.227
C (n=78) 84%
MELD score
<20 (n=69) 92% 0.069
≥ 20 (n=50) 81%
GRWR
<0.8% (n=36)
≥ 0.8% (n=93) 91%
Graft
Right lobe (n=70) 88% 0.535
Left lobe (n=59) 86%
Operative time (h)
<12 (n=30) 89% 0.09
≥ 12 (n=99) 83%
Operative blood loss (L) <10 (n=88) 92% 0.079
≥ 10 (n=41) 81%
Pre-transplant zinc level 
(µg/dL)
<39 (n=58) 84% 0.634
≥ 39 (n=71) 88%
Pre-transplant 
prealbumin level (mg/dL)
<5.4 (n=64) 83% 0.343
 ≥ 5.4 (n=65) 90%
Pre-transplant BCAA 
level (µmol/L)
<375.2 (n=62) 81% 0.476
≥ 375.2 (n=67) 85%
Pre-transplant BTR
<2.92 (n=60) 85% 0.786
≥ 2.92 (n=69) 87%
Pre-transplant tyrosine 
(µmol/L)
<131.7 (n=63) 89% 0.1
≥ 131.7 (n=66) 85%
Pre-transplant total 
lymphocyte count (/µL)
<700 (n=61) 85% 0.698
≥ 700 (n=68) 87%
Pre-transplant ammonia 
level (µg/dL)
<87 (n=61) 90% 0.5
 ≥ 87 (n=68) 85%
BCAA supplementation 
before admission
With (n=66) 91% 0.329
Absent (n=63) 86%
†OS: Overall Survival; BCAA: Branched-Chain Amino Acids; BTR: BCAA-
To-Tyrosine Ratio; GRWR: Graft-To-Recipient Body Weight Ratio; HCC: 
Hepatocellular Carcinoma; MELD: Model for End-Stage Liver Disease; LDLT: 
Living Donor Liver Transplantation
Table 3: Univariate analysis of factors affecting post-transplant patient survival.
that low preoperative skeletal muscle mass was closely involved with 
post-transplant mortality [7]. In the present study, we revealed that 
preoperative BCAA treatment before admission could ameliorate the 
incidence of post-transplant bacteremia and improve post-transplant 
mortality. 
We previously uncovered a significantly negative correlation 
between skeletal muscle mass and the BTR [7]. At that time, we 
speculated that since BCAA are mainly metabolized in the skeletal 
muscle of patients with cirrhosis, more skeletal muscle mass and more 
BCAA consumption would lead to a decrease in the BTR. However, 
the present study identified a significantly positive correlation between 
skeletal muscle mass and BCAA. This finding can be explained by 
the fact that BCAA is also released from skeletal muscle protein due 
to endogenous breakdown under hypercatabolic conditions in liver 
cirrhosis [19]. This represents another source of plasma BCAA beside 
dietary intake in patients with cirrhosis. Therefore, when skeletal 
muscle mass decreases in such patients, BCAA also decreases due to 
skeletal muscle mass depletion. Moreover, the correlation between 
skeletal muscle mass and tyrosine was notably significant and positive. 
Tyrosine was similarly reported to be released from muscle protein 
breakdown [20], however, it is solely metabolized by the liver without 
being metabolized nor consumed by the muscle, probably explaining 
the stronger correlation of pre-transplant skeletal muscle mass with 
tyrosine than with BCAA. Thus, the negative correlation between 
skeletal muscle mass and BTR would be mainly due to positive 
correlation between skeletal muscle mass and tyrosine.
We recently reported that Child-Pugh classification C and massive 
operative blood loss were independent risk factors for post-transplant 
bacteremia [21]. In the present study, in addition to these variables, low 
pre-operative total lymphocyte count and absence of pre-admission 
BCAA therapy were newly revealed to be independent risk factors 
for post-transplant bacteremia. This finding strongly suggests that 
pre-transplant nutritional status is closely involved with the onset of 
post-transplant bacteremia. We are now investigating immunological 
mechanism why pre-transplant nutritional treatment is beneficial to 
prevent post-transplant severe infection.
Some limitations must be borne in mind when considering this 
study. First, BCAA were introduced at the discretion of the attending 
physician before referral of a potential recipient for LDLT. In the present 
study, however, clinical background including Child-Pugh and MELD 
scores between both groups were comparable on admission. Therefore, 
general condition and selection bias might have been at minimum. 
Second, because of retrospective nature of this study, nutritional status 
before BCAA administration was unclear and the exact duration and 
amount of BCAA given within the preoperative nutritional therapy 
protocol were different patient by patient. Prospective randomized 
study to examine the effect of pre-admission BCAA treatment is thus 
needed to adjust these biases. Third, as this was a cross-sectional study, 
we have not completely verified a causal relationship between BCAA 
pre-supplementation and parameter levels on admission. Therefore, it 
will be necessary to perform a future cohort study. Lastly, a limitation 
was reported for BIA in assessment of body water components of 
cirrhotic patients with ascites [22]. Fürstenberg et al reported that BIA 
was highly correlated with other methods in measuring lean body mass 
even in over-hydrated subjects [23]. Moreover, we recently reported 
that the effect of over hydration on overestimation of BIA might 
be, if any, minimum in using this device [24]. At present, therefore, 
segmental multi-frequency BIA used in this study would be best 
modality to assess skeletal muscle mass. 
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Variable Incidence of post-transplant bacteremia P
Recipient Age (y) <60 (n=88) 47% 0.063
≥ 60 (n=41) 29%
Donor Age (y) <50 (n=93) 38% 0.2
≥ 50 (n=36) 50%
Sex Male (n=63) 41% 0.967
Female (n=66) 41%
Original disease HCC (n=36) 42% 0.933
Non-HCC (n=93) 41%
ABO blood type Compatible (n=92) 38% 0.268
Incompatible (n=37) 49%
Child-Pugh A, B (n=51) 24% 0.001
C (n=78) 53%
MELD score <20 (n=69) 48% 0.397
≥ 20 (n=50) 40%
GRWR <0.8% (n=36) 42% 0.933
≥ 0.8% (n=93) 41%
Graft Right (n=70) 47% 0.128
Left (n=59) 34%
Operative time (h) <12 (n=30) 43% 0.775
≥ 12 (n=99) 40%
Operative blood loss (L) <10 (n=87) 33% 0.01
≥ 10 (n=42) 57%
Pre-transplant zinc level (µg/dL) <39 (n=58) 41% 0.951
≥ 39 (n=71) 41%
Pre-transplant pre-albumin level (mg/dL) <5.4 (n=64) 41% 0.916
≥ 5.4 (n=65) 42%
Pre-transplant BCAA level (µmol/L) <375.2 (n=62) 42% 0.85
≥ 375.2 (n=67) 40%
Pre-transplant BTR <2.92 (n=60) 42% 0.9
 ≥ 2.92 (n=69) 41%
Pre-transplant tyrosine (µmol/L) <131.7 (n=63) 37% 0.229
≥ 131.7 (n=66) 47%
Pre-transplant total lymphocyte count (/µL) <700 (n=61) 54% 0.004
≥ 700 (n=68) 29%
Pre-transplant ammonia level (µg/dL) <87 (n=61) 33% 0.07
≥ 87 (n=68) 49%
BCAA supplementation before admission With (n=66) 30% 0.011
Absent (n=63) 52%
†BCAA: Branched-Chain Amino Acids; BTR: BCAA-To-Tyrosine Ratio; GRWR: Graft-To-Recipient Body Weight Ratio; HCC: Hepatocellular Carcinoma; MELD: Model for 
End-Stage Liver Disease; LDLT: Living Donor Liver Transplantation
Table 4: Univariate analysis of factors affecting post-transplant bacteremia.
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Variable Odds ratio   95% CI    P
Child-Pugh classification  C     7.322 1.600-29.996 0.012
Preoperative low total lymphocyte count 
(<700/µL)     5.434 1.313-20.133 0.027
Operative blood loss ≥ 10 L     4.230 1.373-16.763 0.039
Absence of pre-admission BCAA treatment     2.942         1.644-8.643       0.040
†BCAA: Branched-Chain Amino Acids; CI: Confidence Interval
Table 5: Multivariate analysis of factors affecting post-transplant bacteremia.
In conclusion, BCAA therapy before admission could ameliorate 
the incidence of post-transplant bacteremia and could enhance 
improve disease-induced amino acid imbalance or protein status in 
LDLT candidates. Further randomized clinical trials are warranted to 
confirm our hypothesis.
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